Why the study?
Does a sensitive CK-MB immunoassay improve risk stratification for cardiac death in patients with suspected acute myocardial infarction?
Does a sensitive CK-MB immunoassay improve risk stratification for cardiac death in patients with suspected acute myocardial infarction?
A sensitive CK-MB immunoassay identifies a high-risk subgroup of patients with suspected MI who have changing CK-MB levels but do not meet routine MI criteria, revealing a prognosis as poor as confirmed MI.
No takes yet. Share an insight, caveat, or question.
Changing CK-MB levels may identify high-risk suspected MI patients; observational data leaves open whether sensitive assays improve risk stratification.
Ravkilde et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: